Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Eva Kimby, Andrés J.M. Ferreri et al.|Blood|2019Cited by 61
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10Eva Kimby, Emanuele Zucca, Giovanni Martinelli et al.|Blood|2014Cited by 18
Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10Eva Kimby, Emanuele Zucca, Stéphanie Rondeau et al.|Blood|2016Cited by 9
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Emanuele Zucca, Sämi Schär et al.|Blood Advances|2025Cited by 4
PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIALThomas Menter, S Dirnhofer, Alexandar Tzankov et al.|Hematological Oncology|2019Cited by 1